Ativa Biotherapeutics, a U.S. affiliate of GC Cell, has withdrawn its initial public offering plan. Accordingly, the company’s listing on the Nasdaq market has also been delayed.According to the U.S. Securities Exchange Commission, Artiva said Tuesday, local time, that it was withdrawing the securit
As the pharmaceutical industry's business market changed to non-face-to-face after the Covid-19 pandemic, multinational pharmaceutical companies have been reorganizing and reducing their workforce on a global scale.In 2021, Lilly Korea, Roche Korea, and Zuellig Pharma Korea cut jobs mainly in sales
Sanofi-Aventis Korea said it would reduce its workforce through a voluntary early retirement program (ERP)."We aim to have an organization that can respond to customer needs more quickly through a more customer-oriented close collaboration system and future core competency development," a Sanofi off
Korea’s major vaccine makers, including SK Bioscience and GC Biopharma, registered disappointing performances in the third quarter.SK Bioscience disclosed its (provisional) third-quarter business results on Monday. According to the public notice, the company’s sales, operating profit, and net profit
LG Chem has acquired the domestic rights for Vimovo (ingredient: naproxen and esomeprazole), an arthritis treatment developed by AstraZeneca.Vimovo is a product launched in Korea by AstraZeneca Korea in 2012, and has been jointly sold by LG Chem since the early stages of the drug's launch.However, A
After the Ministry of Food and Drug Safety pulled a knife again to rectify the practice of "indirect export" by botulinum toxin makers, the stock prices of the three related companies plummeted on Tuesday.As the Korea Exchange (KRX) decided to suspend the companies' stock trading, the incident's rep
Retail investors of GeneOne Life Sciences said the company was losing its credibility because it failed to meet the Covid-19 pipeline development schedule and its contract manufacturing organization (CMO) sales target.In November 2021, the company announced a capital increase of about 113.8 billion
JW Group said on Tuesday that it signed a joint research contract with Kure.AI Therapeutics, a U.S. bio-venture company, to develop innovative anticancer drugs based on artificial intelligence (AI).Under the agreemment, JW Pharmaceutical and JW CreaGene will start research and development of three n
ST Pharm’s operating profit declined somewhat in the third quarter, drawing the industry's attention.In a public notice, the company said it recorded sales of 60.8 billion won ($42.7 million) and a net profit of 9.9 billion based on the consolidated balance sheet in the July-September quarter.They m
Opdivo (nivolumab), anti-PD-1 immunotherapy co-developed by Ono Pharmaceutical and BMS, has taken its first step as a complete recovery partner for early non-small cell lung cancer (NSCLC) patients in Korea.Last Wednesday, the Ministry of Food and Drug Safety approved the combined administration of
BMS Pharmaceutical Korea has obtained permission for a series of blood cancer treatments this year, increasing its weight in the domestic market.Starting with a nod for the treatment of acute myeloid leukemia, Onureg (azacitidine), in March, it obtained approvals for Inreㅠic (pedratinib), a treatmen
Ferring Pharmaceuticals' recent decision to suspend global shipments of Menopur, an infertility treatment, is likely to bring a shortage of the drug in Korea, officials said.The news comes after Business Insider reported that Elizabeth Garner, Ferring's chief science officer, reportedly sent out an
An Israeli health expert said preventing 19A serotype was an important factor to consider when using pediatric pneumococcal vaccines.Pfizer Korea invited Professor Ron Dagan of Pediatrics and Infectious Diseases at the Ben-Gurion University to speak on the latest regional epidemiological data on pne
OliPass, a Korean company specializing in RNA treatment platform, received an upfront fee of $3 million (4.3 billion won) from Vanda Pharmaceuticals, a U.S. biopharmaceutical company, regarding a joint research and development contract for a new RNA-based treatment.On Sept. 29, the two companies sig
Hugel said the U.S. Food and Drug Administration (FDA) started reviewing its biologics license application (BLA) for Letybo (brand name in Korea: Botulax), its botulinum toxin (BTX) formulation, to treat forehead wrinkles on Tuesday.This is the second time that Hugel filed a BLA for Letybo to the FD
Huons Global said it has signed a memorandum of understanding (MOU) with Lotte Biologics for conducting clinical trials and producing new drug candidates .Under the contract, Huons Global will manufacture and produce investigational biopharmaceuticals at Bristol-Myers Squibb (BMS)’s U.S. plant in Sy
Pharmbio Korea said on Thursday that its Orafang tablet, taken for bowel preparation before colonoscopy, has won a patent in the U.S.Accordingly, the pill developed with domestic technology will be guaranteed exclusive rights to technologies related to the same formulation in the U.S. until May 27,
MSD Korea is strengthening its position in the local antibiotic market with Zerbaxa (ingredient: ceftolozane/tazobactam) after winning reimbursement for the new drug on Oct. 1."Currently, antibiotic resistance is one of the most serious health problems in the world," Professor Choo Eun-joo of the De
HK inno.N is speeding up the launch of a "low-capacity K-CAB tablet," which reduced capacity compared to existing K-cap tablets.The company said Wednesday that it would release "K-CAB tablet 25mg,” which halved the capacity of K-CAB tablet 50mg, next year.K-CAB (tegoprazan) is a new potassium compet
Customized treatment for cancer patients has become possible with the development of immunotherapies.However, Korea’s outdated reimbursement for pathology tests, a prerequisite for using immunotherapy, has become a stumbling block for faster anticancer treatment, pathologists and oncologists said at